Tradestie Institutional Equity Comparison Engine

ACAD vs CRSP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACAD trades at 17.8x Forward P/E with 10.2% operating margin (+22.8% YoY revenue) versus CRSP at 23.4x Forward P/E and -2058.6% operating margin (+1325.1% YoY). In options structure, ACAD sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
ACAD 17.8x vs CRSP 23.4x Fwd P/E
Growth & Margin Winner ACAD
Op Margin 10.2% vs -2058.6% ยท YoY +22.8% vs +1325.1%
Momentum & Technical Winner ACAD
1Y -19.3% vs -20.5% ยท 52W Pos 21% vs 1%
Options & Structure Winner ACAD
BREAKDOWN (4th %ile IV) vs BREAKDOWN (52nd %ile IV)
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$19.07
+1.71% 1D
Market Cap $3.1B
1M Return -0.26%
1Y Return -19.33%
Forward P/E 17.8x
Unified AI Score
42.0 / 100 HOLD
Tech 43.0 Fund 52.0 Flow 68.0 Mom 50.0
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ACAD -19.33% CRSP -20.54% Spread: +1.21 pp (ACAD Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ACAD Revenue CRSP Revenue ACAD Op. Margin CRSP Op. Margin Margin Edge
FY2018 $220M $0M -110.6% -5087.8% ACAD
FY2019 $340M $290M -72.7% 16.1% CRSP
FY2020 $440M $0M -64.9% -49295.5% ACAD
FY2021 $480M $910M -35.2% 40.8% CRSP
FY2022 $520M $0M -43.2% -56190.4% ACAD
FY2023 $730M $370M -10.1% -60.0% ACAD
FY2024 $960M $40M 24.1% -1250.4% ACAD
FY2025 $1.07B $0M 9.8% -18933.6% ACAD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ACAD (6) vs CRSP (4)
Institutional Metric ACAD CRSP Criterion Row Winner
Market Capitalization Scale $3.1B $4.1B Larger Scale CRSP
Trailing P/E Ratio Valuation 8.6x 23.4x Lower Multiple ACAD
Forward P/E Ratio Valuation 17.8x 23.4x Lower Multiple ACAD
Revenue Growth (YoY) Growth +22.8% +1325.1% Higher Growth CRSP
Operating Margin (TTM) Profitability 10.2% -2058.6% Higher Margin ACAD
Net Profit Margin Profitability 30.1% 0.0% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency 31.4% -25.6% Higher ROE ACAD
52-Week Range Position Momentum 21% ($16โ€“$31) 1% ($40โ€“$63) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime 0.11ฮฒ ยท 93% Vol 1.85ฮฒ ยท 60% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 42.0 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ACAD vs CRSP Buy Guide
ACAD BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ACAD nor CRSP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.